1
|
Mian MN, Annam J, Altschuler A, Does MB, Sterling SA, Satre DD, Campbell CI, Asyyed AH, Silver LD, Cunningham SF, Young-Wolff KC. Clinician perspectives on barriers and facilitators to the treatment of adolescent cannabis use: A qualitative study. JOURNAL OF SUBSTANCE USE AND ADDICTION TREATMENT 2025; 169:209559. [PMID: 39522766 PMCID: PMC11772051 DOI: 10.1016/j.josat.2024.209559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Revised: 08/03/2024] [Accepted: 10/29/2024] [Indexed: 11/16/2024]
Abstract
INTRODUCTION Cannabis use among adolescents is prevalent, and clinicians who work with adolescents have unique insights about how to treat cannabis use in this population. METHODS This qualitative study interviewed 32 clinicians from addiction medicine recovery services (AMRS), the emergency department (ED), mental health (MH), and pediatrics in an integrated healthcare system to understand their perspectives and experiences regarding barriers and facilitators to treating adolescent cannabis use. The analysis was developed using thematic analysis of interviews. RESULTS Thirty-two clinicians (Mean age = 45.9, SD =7.6; 56.3 % Female; 56.3 % White) were recruited from AMRS (n = 13; 41.6 %), the ED (n = 7; 21.9 %), MH (n = 7; 21.9 %) and pediatrics (n = 5; 15.6 %). Clinicians discussed several key barriers and facilitators of treating adolescent cannabis use. Facilitators include the use of multiple screening tools for adolescent cannabis use (i.e., self-report and toxicology testing) which provide more comprehensive information; patient-centered treatment approaches; and discussing cannabis use in the context of adolescents' mental health. Barriers discussed included adolescents' and parents' minimization of adolescent cannabis use risks. Several factors were discussed as potential facilitators or barriers, depending on context, including the influence of peers, virtual treatment, and parental involvement or lack thereof in treatment. CONCLUSIONS Interviews with clinicians who work with adolescents across settings highlighted factors that serve as barriers and facilitators to treating adolescent cannabis use. These findings have important implications for guiding future research and intervention efforts, including the inclusion of universal screening practices, addressing stigma, reducing adolescents' and parents' minimization of cannabis use-related harms, and improving adolescent and parent engagement in treatment.
Collapse
Affiliation(s)
- Maha N Mian
- Department of Psychology, Suffolk University, Boston, MA, United States of America; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America.
| | - Jay Annam
- Department of Psychiatry, Kaiser Permanente Oakland Medical Center, Oakland, CA, United States of America
| | - Andrea Altschuler
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America
| | - Monique B Does
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America
| | - Stacy A Sterling
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America
| | - Derek D Satre
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America
| | - Cynthia I Campbell
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America
| | - Asma H Asyyed
- Regional Offices, Kaiser Permanente Northern California, Oakland, CA, United States of America
| | - Lynn D Silver
- Public Health Institute, Oakland, California, United States of America
| | - Sarah F Cunningham
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America
| | - Kelly C Young-Wolff
- Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, United States of America; Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, CA, United States of America
| |
Collapse
|
2
|
Buschner M, Heckel N, Dürler P, Engeli EJE, Schneider S, Havelka EM, Nordt C, Herdener M. The Züri Can study: Can regulated cannabis sales promote lower-risk cannabis use? Mini-review and study protocol. THE INTERNATIONAL JOURNAL OF DRUG POLICY 2024; 133:104610. [PMID: 39395284 DOI: 10.1016/j.drugpo.2024.104610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 09/30/2024] [Accepted: 09/30/2024] [Indexed: 10/14/2024]
Abstract
BACKGROUND AND AIMS Recreational use of cannabis is illegal in most countries. Despite this, it is the third most commonly used psychoactive substance worldwide. As a result of this discrepancy, a growing number of countries have begun to reassess their legal approach to cannabis in recent years. While the health risks of cannabis and potential harm reduction measures are increasingly well understood, there are still significant gaps in knowledge about which regulatory and supply models are effective in promoting lower-risk cannabis use. In this paper, we outline the Züri Can study, which implements and evaluates a regulatory framework for cannabis sales in the city of Zurich, Switzerland, between 2023 and 2026. In addition, we illustrate how the study addresses current knowledge gaps to provide further insight into the potential future regulation of cannabis in Switzerland. To embed the study in the present scientific and political context, we first provide a brief overview of the state of knowledge on cannabis-related health risks and means of reducing them, along with lessons learned from other countries that have implemented varying regulatory systems. DESIGN AND MEASUREMENTS 2,100 participants will be able to legally purchase cannabis either at a pharmacy, a cannabis social club, or the municipal drug information center over a three-year period. As part of this observational study, participants will be evaluated regarding their cannabis use habits and motives, their knowledge of lower-risk use, and their mental and physical health, among other parameters. Established harm reduction strategies are implemented as an integral part of the study design. COMMENTS The study will contribute to a better understanding of the impact of different cannabis distribution models on cannabis use patterns and related health outcomes. The results are expected to assist Swiss and international policy makers in developing evidence-based and public health-oriented regulatory frameworks for cannabis.
Collapse
Affiliation(s)
- Maximilian Buschner
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland.
| | - Nadine Heckel
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Patricia Dürler
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Etna J E Engeli
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Sophie Schneider
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Eva M Havelka
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Carlos Nordt
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| | - Marcus Herdener
- Center for Addictive Disorders, Department of Adult Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Selnaustrasse 9, 8001 Zurich, Switzerland
| |
Collapse
|
3
|
Nali MC, Yang JS, Li Z, Larsen MZ, Mackey TK. Cannabis-Derived Product Types, Flavors, and Compound Types From an E-Commerce Website. JAMA Netw Open 2024; 7:e2440376. [PMID: 39432307 PMCID: PMC11581530 DOI: 10.1001/jamanetworkopen.2024.40376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2024] [Accepted: 08/27/2024] [Indexed: 10/22/2024] Open
Abstract
Importance Cannabis-derived products (CDPs) are widely available and diverse. A classification of product and flavor types is necessary to establish a foundation for comparative research, although research aiming to classify cannabis in its variety of products, flavors, and cannabinoid compounds based on public online e-commerce data is lacking. Objective To analyze data from a large cannabis e-commerce marketplace to identify and characterize cannabis product types, flavors, and compound types. Design, Setting, and Participants This qualitative study was conducted in 2 phases: (1) data mining of the cannabis e-commerce website Weedmaps for product listings in the US between September 1 and November 30, 2023 and (2) grouping CDPs into product, flavor, and cannabinoid compound categories. Exposures Cannabis product listings. Main Outcomes and Measures Product listings and descriptions were extracted from the platform. Coding was performed for specific product characteristics, routes of administration (ROAs), and characterization of flavors. Results A total of 573 854 unique US CDP sales listings from the platform were collected; after removing 72 842 nonconsumable items, 501 012 were analyzed. Product ROAs included multisystem (205 637 [41.04%]), respiratory (185 296 [36.98%]), digestive (98 941 [19.75%]), epidermal (9487 [1.89%]), and oral (1651 [0.33%]). Nearly half (210 575 [42.03%]) of all product listings included at least 1 flavor, with 247 762 instances of flavors. The 3 most common flavors were lemon (22 106 [8.92%]), cake (19 463 [7.86%]), and strawberry (13 961 [5.63%]). The most common cannabinoid compound type was Δ9-tetrahydrocannabinol (54 699 [63.30%]). Conclusions and Relevance This qualitative study categorized more than half a million CDPs for product and flavor types. Results are needed for comparative studies on product and market availability and can help in assessing concerns about appealing characteristics. The results can also inform future market surveillance efforts aimed at identifying new and emerging products as cannabis policy continues to move toward greater legalization.
Collapse
Affiliation(s)
- Matthew C Nali
- San Diego Supercomputer Center, University of California, San Diego
- Global Health Policy and Data Institute, San Diego, California
- S-3 Research, San Diego, California
| | - Joshua S Yang
- Department of Public Health, California State University, Fullerton
| | - Zhuoran Li
- San Diego Supercomputer Center, University of California, San Diego
- S-3 Research, San Diego, California
| | - Meng Zhen Larsen
- San Diego Supercomputer Center, University of California, San Diego
- S-3 Research, San Diego, California
| | - Tim K Mackey
- San Diego Supercomputer Center, University of California, San Diego
- Global Health Policy and Data Institute, San Diego, California
- S-3 Research, San Diego, California
- Global Health Program, Department of Anthropology, University of California, San Diego
| |
Collapse
|
4
|
Chaffee BW, Couch ET, Donaldson CD, Farooq O, Cheng NF, Ameli N, Zhang X, Gansky SA. Patterns in Tobacco, E-Cigarette, and Cannabis Advertising Exposure Among California Adolescents and Associations With Future Use Expectations. Subst Use Misuse 2024; 59:1240-1248. [PMID: 38509707 PMCID: PMC11045304 DOI: 10.1080/10826084.2024.2330912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
BACKGROUND Exposure to tobacco, e-cigarette, or cannabis marketing is associated with adolescent use. Few studies have examined advertising exposure prevalence and patterns across these products concurrently. METHODS This study assessed past 30-day recalled exposure to promotional messages about tobacco, e-cigarettes ("vapes" on the survey), and cannabis ("marijuana") from various sources among California adolescents (ages 12-17) in the 2022 Teens, Nicotine, and Tobacco Online Survey (N = 2530). Principal components analysis (PCA) was conducted to examine the underlying structure and patterns in advertising exposure sources. Multivariable logistic regression was used to evaluate associations between any advertising exposure and future use expectations (a susceptibility measure) in one year and at age 25 among current never-users. RESULTS Overall, 65.9% of participants recently noticed at least one tobacco (52.5%), vape (51.5%), or marijuana (45.6%) advertisement. Gas stations or convenience stores were the most common source for tobacco or vape ads; billboards were for marijuana ads. In PCA, advertising exposure patterns correlated with advertising source, not the type of product. Exposures from tobacco-specific sources and nearer point of sale were associated with current use, older age, LGBTQ + identity, and sensation seeking. Among never-users, advertising exposure was associated with one-year and age-25 use expectations for cigarettes (one-year expectations adjusted odds ratio: 1.7; 95% CI: 1.1, 2.5), vapes (2.3; 1.5, 3.5), and marijuana (2.1; 1.5, 3.0). CONCLUSION California adolescents' exposure to tobacco, e-cigarette, and cannabis marketing is common, follows similar patterns, and is associated with use susceptibility. Comprehensive restrictions on marketing accessible to adolescents could help prevent youth use.
Collapse
Affiliation(s)
- Benjamin W. Chaffee
- Center for Tobacco Control Research and Education, University of California San Francisco, 530 Parnassus Avenue, Suite 366 Library, San Francisco, CA, USA 94143
- Division of Oral Epidemiology and Dental Public Health, University of California San Francisco, 707 Parnassus Avenue, D3214 Box 0758, San Francisco, CA, USA 94143
| | - Elizabeth T. Couch
- Center for Tobacco Control Research and Education, University of California San Francisco, 530 Parnassus Avenue, Suite 366 Library, San Francisco, CA, USA 94143
- Division of Oral Epidemiology and Dental Public Health, University of California San Francisco, 707 Parnassus Avenue, D3214 Box 0758, San Francisco, CA, USA 94143
| | - Candice D. Donaldson
- California Tobacco Prevention Program, California Department of Public Health, CHC/California Tobacco Control Branch, MS 7206, P.O. Box 997377, Sacramento, CA, USA 95899
| | - Omara Farooq
- California Tobacco Prevention Program, California Department of Public Health, CHC/California Tobacco Control Branch, MS 7206, P.O. Box 997377, Sacramento, CA, USA 95899
| | - Nancy F. Cheng
- Division of Oral Epidemiology and Dental Public Health, University of California San Francisco, 707 Parnassus Avenue, D3214 Box 0758, San Francisco, CA, USA 94143
| | - Niloufar Ameli
- Division of Oral Epidemiology and Dental Public Health, University of California San Francisco, 707 Parnassus Avenue, D3214 Box 0758, San Francisco, CA, USA 94143
| | - Xueying Zhang
- California Tobacco Prevention Program, California Department of Public Health, CHC/California Tobacco Control Branch, MS 7206, P.O. Box 997377, Sacramento, CA, USA 95899
| | - Stuart A. Gansky
- Center for Tobacco Control Research and Education, University of California San Francisco, 530 Parnassus Avenue, Suite 366 Library, San Francisco, CA, USA 94143
- Division of Oral Epidemiology and Dental Public Health, University of California San Francisco, 707 Parnassus Avenue, D3214 Box 0758, San Francisco, CA, USA 94143
| |
Collapse
|